Results for tag: "Sensipar"

Sensipar (Cinacalcet) is a drug used to treat secondary hyperparathyroidism (SHPT) in patients with chronic kidney disease (CKD) and end-stage renal disease (ESRD) on dialysis, as well as hypercalcemia in patients with parathyroid cancer. It is also used to treat hypercalcemia in patients with primary hyperparathyroidism (PHPT) who are unable to undergo parathyroidectomy. Sensipar works by blocking the action of parathyroid hormone (PTH) on the bones, kidneys, and intestines, thereby reducing the amount of calcium in the blood. The Sensipar market is a subset of the larger Liver and Kidney Disorders Drugs market. It is a growing market, driven by the increasing prevalence of chronic kidney disease and end-stage renal disease, as well as the need for effective treatments for hypercalcemia. Companies in the Sensipar market include Amgen, Inc., AstraZeneca, Bristol-Myers Squibb, Daiichi Sankyo, Inc., Eli Lilly and Company, GlaxoSmithKline, Merck & Co., Inc., Novartis AG, Pfizer, Inc., and Takeda Pharmaceutical Company Limited. Show Less Read more